immunotherapy
The findings of a recent study suggest that the combination of anti-PD-1 immunotherapy with a lack of TREM2 generates a gut environment that promotes inflammation, which improves tumor rejection.
The findings uncover a link between vitamin D, the immune system and gut bacteria, and they suggest that vitamin D levels could be important for cancer immunity and the efficacy…
The findings of a recent study suggest that L. johnsonii or its metabolite IPA could be used as a microbial-based approach to improve a person’s response to immunotherapy.
Johan van Hylckama Vlieg, CSO and Co-founder of Freya Biosciences, discusses the latest advancements in microbial immunotherapies for women's health.
The findings of a recent study suggest that antibiotics should be prescribed with caution in cancer patients who are planning to receive PD-1 inhibitors.
In a significant move to expand its immuno-oncology portfolio, Boehringer Ingelheim has acquired T3 Pharmaceuticals AG, a Swiss biotech company specializing in bacterial cancer therapy.
The findings show that bacterial metabolites can sensitize cancer cells to treatment with immunotherapy by boosting the expression of HLA class I molecules.
Understanding how antibiotics influence the microbiota’s impacts on immunotherapy may inform strategies to identify cancer patients that are more likely to respond to cancer treatment.
The findings of a recent study suggest that FMT is an effective strategy to mitigate the intestinal side effects of cancer immunotherapy.
Pedro Correa de Sampaio, Chief Executive Officer at Neobe Therapeutics, talks about the challenges to remove immunosuppressive constraints that prevent the infiltration of immune cells in a subset of cancers.
